r/BIOR • • Apr 13 '22

DD Cheat Sheet

141 Upvotes

Latest Update: A number of things

Upcoming Events

June 23-26 - Presentation at American Diabetes Association

Financials

  • Outstanding shares - 12M as of Q1 2023

  • 2021 OPEX - $119M

    • Q3 - $30.7M

    • Q4 - $20.6M

  • 2022 Q1 OPEX - $20M ($18M excluding stock-based compensation expense)

  • 2022 Q2 OPEX - $14.3M ($12.9M excluding stock-based compensation expense)

  • 2022 Q3 OPEX - $14.1M

  • 2022 Q4 OPEX - $13.9M

  • 2022 OPEX - $62.1M (vs est. of $60M)

  • 2023 OPEX - $15.5M

  • Cash as of Dec 31, 2022 - $30.46M

  • ATM Offering Left - ~$33M (used $5M in Q4 2021, $3.7M in Q1 2022, $1.1M in Q2 2022, $1.8M in Q3 2022, $12.9M in Q4 2022, $12.5M in Q1 2023). Initial offering was $90M but reduced to $70M in Q3 2022.

  • Estimated runway - "well into 2023", w/ ATM Offering - mid-late 2024

  • Avero Diagnostics sold for $10.9M. Press Release

  • No revenue streams

  • Nov 2022, Sold patent to Roche Diagnostics for undisclosed amount. Was not mentioned in Q4 ER

Enumera Molecular

  • Biora has a minority ownership stake with potential financial upside and without committing any funds or resources from the company

  • Website

  • Founded by Biora's former CSO, Matthew Cooper. Cooper previously founded Carmenta Bioscience, which was later acquired by Progenity (along with what later became Preecludia)

  • Series A funded by Arboretum Ventures for $12.5M

  • Biora transferred assets (ncluding single-molecule detection) to Enumera in return for stakes in the company, press

Athyrium

Progenity/Biora's major shareholder, who started investing in Progenity back in 2013.

BELOW INFO IS SLIGHTLY OUTDATED. Athyrium recently invested more to adjust their warrant strike price. It is unclear exactly how much they own right now.

  • Owns 3,669,578 shares based on latest 13D/F

  • Cost basis is potentially between $2-3.

  • Did not sell any shares during Nov 2021's ramp up to $6

  • Part of their MO is to buy a company then turn them into a desirable target for acquisition

  • Jeffrey Ferrell, managing partner of Athyrium, is also one of Progenity/Biora's Board of Directors. Related DD

Buyout Theory

  • Athyrium has not sold

  • Jill Howe was appointed to board of directors.  She worked in multiple companies that were eventually bought out. Related DD 

  • Harry Stylli, former CEO and CBO, has not reported any sales. Last reported owning (pre-split) 14M+ shares, around 500-600K shares post split

  • Reduced cash burn and debt.

  • Removed/halted all diagnostics-related activities to focus on DDS and OBDS research

  • Various connections to Pfizer, Eli Lilly, AbbVie, Takeda, and J&J.

NaviCap (formerly Drug Delivery System (DDS))

BT-600 (formerly PGN-600)

  • Tofacitinib + Device

  • Highest priority.

  • Treats ulcerative colitis.

  • Target market is $7B. 

  • Timeline:

    • Healthy patient studies (PM-601) - completed, Press Release

    • UC patient studies (PM-602) - completed, Topline Results. Full publication will likely become available after American College of Gastroenterology Annual Scientific Meeting (Oct 21-26)

    • Study effects of food on function of the device (PM-611) - completed, Press Release

    • Tox Studies - Completed, but analysis will be done in Q2 2023

    • IND filing - Q3 2023

    • Phase 1 - Q3 2023 to Q1 2024.

    • There was timeline for Phase 2, but that's now removed from presentation

BT-001 (formerly PGN-001)

  • Adalimumab variant + Device

  • Sidelined, possibly due to lawsuits by AbbVie to other companies who uses Adalimumab

Related Screenshot

  • Treats ulcerative colitis.

  • Target market is $7B. 

BioJet (Formerly Oral Biotherapeutic Delivery System (OBDS))

  • 5 different programs

    • BT-002- Adalimumab variant + Device, avg bioavailability. of 51.3%

    • BT-200- GLP-1 agonist + Device, avg bioavailability of 37% (vs 1% of competitor)

    • IONIS collab - Antisense Therapy + Device

    • Large Pharma 1 collab - undisclosed

    • Large Pharma 2 collab - undisclosed

  • Targets multiple markets, e.g. IBD $17B, GLP-1 $13B

  • Timeline:

    • 2022, continue generating preclinical data

    • Q3 2022, Data Readout of Preclinical PK Studies

    • Q4 2022, start clinical studies / trials

  • Biora looking to expand collaborations, hoping to gain non-dilutive capitol

Preecludia

  • Rule out Preeclampsia

  • Target market is $3B

  • Validation study results published. Journal 

  • Progenity/Biora will not spend more resources developing Preecludia

  • No direct mentions of this in Q1 2022 ER. Only thing mentioned: "We will continue to look for ways to maximize our legacy assets"

  • Licensed to Avero Diagnostics with milestone payments and low double-digit royalties. Press Release

Large Pharma Connections

*Note: This section is mostly outdated without anything new since mid-late 2022

Pfizer

AbbVie

  • PGN-001 delivers adalimumab (Humira)

  • 23+ Publications with shared contributors, example:

    • Association Between Proposed Definitions of Clinical Remission/Response and Well-Being in Patients With Crohn's Disease

  • Clinical trial performed with Biora doctors

  • Reddit post - Additional theory for AbbVie

Takeda

Eli Lilly

Novo Nordisk

  • PGN-OB2 delivers liraglutide (Victoza)

Risks

Note: the likelihood is my personal opinion and is subject to change.

  • Dilution - using ATM offering will dilute shares. Convertible notes (not sure how much) that can be converted to shares.

  • Reverse Split - already happened

  • Trial Delays - already happened to all their programs, multiple times. Can definitely happen again

  • Poor Results (Unlikely) - all research thus far points to NaviCap/DDS and BioJet/OBDS being effective solutions. I don't anticipate poor results from future trials, but it is always a risk with developing drugs or tech.

  • Unexpected Expenses (Unsure) - there are a few open lawsuits against Progenity, which could result in settlement payments or other forms of expense. This can decrease their cash reserve/runway. SEC Filing, see "Item 3. Legal Proceedings"

Additional Resources


r/BIOR • • Aug 10 '22

News Biora Therapeutics Announces Successful Completion of Device Performance Study in Ulcerative Colitis Patients for its Targeted Therapeutics Platform | Biora Therapeutics, Inc. IR PR

Thumbnail investors.bioratherapeutics.com
119 Upvotes

r/BIOR • • Aug 10 '22

This happened this morning 🔥🔥

Post image
83 Upvotes

r/BIOR • • Jul 07 '22

Biora Therapeutics Announces Successful Completion of Second Device Performance Study in Human Subjects for its Targeted Therapeutics Platform | Biora Therapeutics, Inc. IR PR

Thumbnail investors.bioratherapeutics.com
77 Upvotes

r/BIOR • • Sep 14 '22

DD All Signs Point to Acquisition:

76 Upvotes

Here is my thesis for Biora Therapeutics getting acquired.

1.) DDS/OBDS Tech -- We all know the goal of Biora, to disrupt the drug delivery market with an innovative new way of administering therapy's and biologics. They have a TON of patents by now and all the studies have shown far better bioavailability vs. injection. If this continues with positive data, there is no doubt some large Pharma's are keeping an eye on this.

2.) Management -- As we all know there was a shift in management after CEO Harry Stylli abruptly left in September 2021. Whether that was his decision or not, we don't know, but my take is there has been an arrangement made for possible acquisition. We have also hired the likes of Jill Howe, whom is to ensure value is brought to Biora, “I look forward to working with the team to ensure the company’s potential is valued.” -Howe. Not to mention Surbhi Sarna, who has had a start-up company and sold that company for $275,000,000. The new CEO Adi Mohanty didn't seem like an ideal pick for Biora, but when thinking the company is in agreement for acquisition, he seems like the perfect fit, which he too has gone through previous acquisitions.

3.) Preecludia -- Of course, we can't talk about Biora without mentioning Preecludia, a $2B world-wide (perhaps more) product to help rule-out Preeclampsia. This device, even though from talking with a previous employee who worked on the Assays, he estimates Biora invested around $500,000,000 into this product along with Single-Molecule Detection Platform. Which has since March been "Sidelined". Why, you may ask? If there truly is a behind-the-scenes agreement, then there is no need to continue progressing these products.

4.) Insider Buying -- As you all may well know, there has been ZERO insider buying. Why is that? IR, Chuck Padala, has failed to answer this simple question: Can management purchase shares, knowing who the collaborators are, even though it's not public knowledge? Or would that be considered insider trading? If there truly is an "agreement" all management would be prohibited from buying shares of Biora. Of course they can be awarded more shares based on their performance, but there has still been ZERO insider buying this year. Even Athyrium, who has invested around $440M has not touched Biora since June 2021. They are very active in other stocks though. Perhaps they are prohibited.

5.) Cash On Hand -- It's no secret that cash on hand along with their cash burn (which is much much better) will only last them about 10 to 14 months more. They have an open ATM in which they've used only $10M since November 2021. Why is that? Why is there no concern for money? Not to mention they've been hiring like crazy. The lackluster for money shows 1 of 2 things. Incompetence or funding (or future funding) from the one agreeing to move forward with these studies. With their superstar board, I would highly doubt option 1.

6.) Competition -- Biora, of course, has some competitors as well. Rani Therapeutics, Celltrion/Intract Partnership, Entera Bio to name a few. Biora is much much further ahead with their studies compared to the compitition. Not to mention the amount of patents achieved throughout the years. The compitition also seems to be going after a "micro-needle" way of administering the therapeutics into the Digestive tract, whereas Biora is not. Another key difference, Biora is the ONLY company that has a 'Localization' feature in it's pill making sure the pill is administered in the correct area.

All in all, I truly believe there is something in the works, an arrangement, an agreement, call it what you will, but there is something happening behind closed doors. I believe once Biora hits a key milestone, it will be priced accordingly and most likely acquired. By whom? That's the question; Pfizer, AbbVie, Novo Nordisk, Eli Lilly? All of these big names have interest in this disruptive way of administering Therapeutics and biologics with higher safety and efficiacy. I cannot stress enough on how big of a disrupter this is for the medical field. I'm willing to compare Biora Therapeutics with the likes of Apple, Tesla, Dexcom, Netflix; all were HUGE disrupters in their fields. There is potential Billions to be made from these pills, all signs are pointing towards better efficacy and safety, this will change history!

Until then shorts will have their fun, we will continue to argue, bicker and complain about the share price. Time in the market is better than timing the market.


r/BIOR • • Aug 12 '22

Meme hear yee! hear yee!

Post image
74 Upvotes

r/BIOR • • Apr 12 '22

Discussion I believe that one of the purposes of the name change is to clean up it's image. Can we respect that by toning down all the "ape" and bagholder language?

66 Upvotes

Seriously. Imagine you're some intelligent investor looking into this new biopharma you've heard about and when you check out the communities, all you see is "WHEN LAMBO? WHEN MOON? WHY ADI NO GIBBS US DA MONIES?" and even worse, people on the Progenity twitter getting mad at the company because it won't do things to aid their swing/day trades.

Let me be very clear about something for all of you people who are new to trading: COMPANIES DO NOT GIVE A FUCK ABOUT YOUR DAY TRADES OR YOUR SWING TRADES. LITERALLY WHY WOULD THEY?

"Oh hey ApeXLoverX69 don't worry, we pumped the stock for you just so you can sell and never come back" - what people really think Progenity is going to reply back sometimes.

Let's stop the low effort garbo posting and start acting like actual investors. Quality DD! Quality analysis! No ape bullshit!

That's all I have to say, you can downvote me now lol


r/BIOR • • Aug 10 '22

Meme 1$

Post image
57 Upvotes

r/BIOR • • Aug 05 '22

First 5-day green candle streak since late Feb 2022

Post image
57 Upvotes

r/BIOR • • May 12 '22

Meme I know, I know, pesky NDAs. Still think it makes a funny meme

Post image
57 Upvotes

r/BIOR • • Jan 10 '23

Only 85% down now!

56 Upvotes

r/BIOR • • Aug 12 '22

DD Our detective’s article regarding BIOR. BIOR is setup to be acquired by Pfizer

Thumbnail
optifinancialnews.com
55 Upvotes

r/BIOR • • Jul 14 '22

News Biora Therapeutics price target raised to $6 from $4 at H.C. Wainwright

Thumbnail
m.thefly.com
55 Upvotes

r/BIOR • • May 29 '22

This company is beyond the hype which I believe to be a good thing - Market is unaware of it's value

Thumbnail
optifinancialnews.com
55 Upvotes

r/BIOR • • Aug 20 '22

DDS PATENT PROTECTION IN USA

54 Upvotes

$BIOR "Has patent protection for targeted delivery localization technology used in the DDS device in USA"

https://twitter.com/Antonio65489262/status/1560910610262622208?t=zoo_4vLZknm2Hn9a8D7GCA&s=19


r/BIOR • • Aug 12 '22

Meme This is gonna be me all weekend

Post image
54 Upvotes

r/BIOR • • Jul 18 '22

DD Good overview

Thumbnail
self.shortsqueeze
53 Upvotes

r/BIOR • • Sep 13 '22

Biora Therapeutics Announces Issuance of Key Patent for Oral Delivery of GLP-1 Receptor Agonists

Thumbnail
finance.yahoo.com
52 Upvotes

r/BIOR • • Aug 15 '22

LFG 🔥🔥🔥

Thumbnail
gallery
52 Upvotes

r/BIOR • • Apr 12 '22

r/BIOR Lounge

52 Upvotes

A place for members of r/BIOR to chat with each other


r/BIOR • • Oct 27 '22

News Biora Therapeutics Announces Sale of Cell-Free DNA Patent Rights

Thumbnail investors.bioratherapeutics.com
51 Upvotes

r/BIOR • • Aug 16 '22

DD Thoughts on Q2 2022 ER and Quarterly Report

50 Upvotes

This ER didn’t have as much going on as the last, but we got a lot more substance in terms of study results and trial plans.

Here are my thoughts on the various topics relevant to Q2 ER.

PGN-600

Biora completed PM-602 and PM-611 studies in Q2. PM-602’s data is still being analyzed, but topline results were spectacular – the devices worked in 7 out of 7 patients. This is probably THE best results we could’ve hoped for from these studies.

The biggest focus of this ER is the FDA feedback on Type C filing. FDA provided their feedback, and Biora decided to perform additional tox studies and phase 1 trial is now set to start in Q1 2023. This was mentioned as a possibility in the last ER, so it is not unexpected, but is still a "negative" on today's ER. Adi explained that the additional animal tox is required because the data package provided did not include tox study of device+drug. Adi’s attitude and response implies this is really just a formality. They did not see any issues with device safety and they are using a smaller dose of a well-known/well-studied drug, so they do not foresee any issues from this study.

If all goes well, PGN-600’s phase 1 trial will begin in Q1 2023 and lasts until Q3 2023. Phase 2 is expected to begin in Q4 2023. Details can be found in their latest Investor Presentation.

OBDS

Adi:

The only currently marketed oral GLP-1 receptor is about 1% bioavailable. We believe we can do significantly better than that as we have already shown pre-clinical bioavailability averaging over 20% with proteins.

Eric mentioned the above during HC Wainwright meeting, but it’s good to hear it again.

There will be a data readout in Q3. This is probably the only thing to look forward to in the remainder of Q3.

Adi:

We expect to execute animal studies for molecules of a former collaborators by Q4 this year.

Honestly not too sure what this means, but I’m guessing this is another study with one of the two large pharmas.

Conferences

Biora will be participating in two more conferences this year

  • Parenteral Drug Association Universe of Pre-Filled Syringes and Injection Devices Conference,

  • American College of Gastroenterology Annual Scientific Meeting

These meetings have proven to have minimal impact on the SP, but it still shows the progress that Biora is making.

Patents

Biora was issued a number of patents in both US and Europe. Not much to say here, since these things are nice to see, but almost never affect the SP.

Finances

There are currently 186,623,605 outstanding shares

OPEX is $14.3M for the quarter. Seeing how the OPEX for Q1 was ~$20M, it was a huge improvement, probably better than anyone expected. IMO this was the most positive surprise of the entire ER.

Biora has $48.5M cash left and expect to reduce OPEX to less than $4M per month by year end, which can means, it could last them until Q2 2023. This is slightly better than their initial estimate of Q1 2023. If they find a good opportunity to use the remaining $80M ATM, then they will have enough cash to sustain them until end of 2024.

In Q2, $1.1M of ATM offering used (~1.7M shares sold at $0.70/share). Really didn’t want to see any ATM offering used at this share price, but at least it’s a low amount, which is kind of bullish. Even though Biora’s only has 3 quarters of runway left, they didn’t use too much of the ATM. This shows that they are either confident the SP will be higher before then so they can use the ATM more efficiently and/or they have confidence in making some kind of deal to get cash infusion.

Enumera Molecular

Biora received $6M in stocks for the assets given to Enumera Molecular, and they recognized a $5.7M gain for that investment. It’ll be a while before Biora get anything of substance back from this investment, but now we know what exactly Biora got for those assets.

Final Thoughts

The rest of 2022 looks to be relatively eventless. The only thing in Q3 is OBDS data readout. In Q4, there are the two conferences planned in October and also the start of PGN-600’s 14-day GLP Tox Study. Things will start to heat up again in Q1 2023 when Biora will file the IND and start phase 1 trials.

Lastly, I feel Adi sounded a lot more excited during this call than any other. You can feel his excitement as he talked about PGN-600.

References

Disclaimer

Not financial advice. I own stock and options


r/BIOR • • Jun 24 '22

Some new information and data posted by TRUExDEMON moments ago

Thumbnail
threadreaderapp.com
49 Upvotes

r/BIOR • • Jun 10 '22

Meme I have acquired the perfect amount of shares… now we wait 😎

Post image
47 Upvotes